We Think Atossa Therapeutics (NASDAQ:ATOS) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Atossa Therapeutics Maintains Strong Market Position for (Z)-Endoxifen for Duchenne Muscular Dystrophy as Congress Reauthorizes Priority Review Voucher Program

Atossa's Rare Pediatric Disease Designation for (Z)-endoxifen in neuromuscular diseases qualifies for a future PRV upon FDA approval SEATTLE, Feb. 5, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc.

Atossa Therapeutics Issues Letter to Shareholders Highlighting 2025 Accomplishments and 2026 Outlook

We were honored to receive the 2025 Clinical Trials Arena R&D Excellence Award in the Precision Endocrine Therapy category, reflecting growing awareness of the utility of (Z)-endoxifen across oncology ...
Fintel on MSN

Atossa Therapeutics (ATOS) price target increased by 1,400.00% to 87.98

The average one-year price target for Atossa Therapeutics (NasdaqCM:ATOS) has been revised to $87.98 / share. This is an increase of 1,400.00% from the prior estimate of $5.86 dated January 11, 2026.
CNN

Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture

SEATTLE, May 20, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to discover and develop innovative medicines in areas of ...
CNN

Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density

SEATTLE, March 02, 2020 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and ...
Seeking Alpha

Atossa jumps 17% after update on mid-stage trial for breast cancer drug

Atossa Therapeutics (NASDAQ:ATOS) added ~17% to rise sharply for the second straight session on Wednesday after announcing that enrollment in a mid-stage trial for its experimental breast cancer ...
Nasdaq

Atossa Therapeutics Responds to PTAB Decision on Patent No. 11,572,334 and Announces New Patent Issuance

Atossa Therapeutics, Inc. expressed disappointment over the Patent Trial and Appeal Board's ruling deeming all challenged claims of U.S. Patent No. 11,572,334 unpatentable. While Atossa will not ...